Investigating How GLP-1 Medications Impact Strength and Recovery

The conversation about GLP-1 drugs, medications like semaglutide and tirzepatide, has largely focused on the number on the scale, understandably, as the biological mechanisms driving that weight loss are pretty incredible. As millions of people settle into long-term use though, a separate set of questions is emerging that the weight-loss framing often doesn't address.

What happens to the tissues changing alongside the fat, and what does that mean for the signals we rely on to understand readiness, recovery, and how we truly feel? These shouldn’t be side-issues. They're central to how we operate day-to-day and how our body adapts, or doesn't, over months of use.

The Tissue Math That Gets Overlooked

When our body loses weight rapidly, it doesn't classify neatly between fat and everything else. Lean mass, which is the collective term for muscle, bone, connective tissue, and organs, also declines. The degree varies based on multiple factors, including protein intake, training load, and individual genetics, but studies consistently show that a meaningful proportion of total weight lost during GLP-1 use comes from lean tissue, not fat alone. In some populations, lean mass losses account for 25 to 40 percent of total weight lost.

Lean mass is what powers our physical state. Muscle produces force, generates heat, and manages glucose under exercise stress. It also contributes to the metabolic rate that determines how our body handles energy over time (i.e. how many calories we burn). When that mass erodes quietly alongside fat, the person losing weight may feel lighter without feeling more capable. In some cases, they may feel less capable and energetic without a clear explanation for why.

The complicating factor is that GLP-1 medications suppress appetite substantially, often to the point where eating takes intentional effort. Getting sufficient protein, which is largely responsible for preserving muscle, becomes harder precisely when it matters most. Our biology can end up working against itself, where appetite suppression reduces caloric intake, which drives weight loss, which also reduces at lean mass, which the suppressed appetite makes harder to protect.

What This Does to Recovery Signals

Recovery is a physiological process, but we experience it as a “readiness state,” often thought of as a felt sense of whether we’re prepared to meet the physical, cognitive, or emotional demands being placed on us. That felt sense is shaped by sleep quality, hormonal regulation, autonomic nervous system tone, and the accumulated burden of recent training load.

GLP-1’s interact with several of those inputs in ways that aren't yet fully mapped. The receptors these medications target aren’t confined to the gut and pancreas. They're actually distributed throughout the body, including in the brain regions that regulate appetite, reward processing, and autonomic function. Some early research suggests that GLP-1 receptor activation may influence the part of our nervous system associated with activation and stress response, though the direction and magnitude of those effects seem to vary considerably between individuals.

What this means practically is that our body’s approach to recovery may shift. A person using these medications for several months is not the same physical system they were before starting. Their ability to regulate stress may be altered. Their hormonal environment is different. Their lean mass is lower. The signals that would previously have indicated "recovered" or "not recovered" are being generated by a system that has changed in multiple ways at once.

Strength Under Shifting Conditions

When it comes to physical training, the use of these drugs can have a variety of impacts. Increasing strength in the weight room is a function of exposing our muscles to resistance, which triggers our body to synthesize new protein and, over time, increasing the strength of the muscle. That adaptation process requires two things running in parallel, 1.) adequate stress/resistance on the given muscle and 2.) enough of the right fuel, primarily protein and total calories.

Both are disrupted under conditions of caloric restriction, which is the main outcome of using weight loss drugs. We can still train, but the adaptive response that leads to improvement is blunted if protein intake isn't sufficient to support it. Training hard while under-eating in the wrong way doesn't just fail to build muscle; it can accelerate the lean mass losses already occurring from the weight loss drug itself.

This creates a situation where standard training tolerance markers become unreliable guides. Someone may train at intensities that would previously have felt easy, but now experience greater perceived exertion, longer recovery times, and less visible improvement. Fatigue accumulates faster when the tissue being stressed struggles to regenerate between sessions.

The signal that something is off often arrives after the fact, once our decline is already noticeable. The drift happens first with our awareness of the change only catching up after the fact.

Reframing GLP-1 Medications

None of this means GLP-1 medications are incompatible with performance. They do exactly what they’re designed and marketed to do. The weight loss is real, and for many people, the metabolic improvements are substantial. The core question isn't whether the medications are working; that’s already pretty obvious. The underlying issue is what is our body actually adapting to, and how does that change our training, recovery, and long-term physical development?

The assumptions underlying most strength and recovery frameworks were built on stable-state physiology, meaning the training itself is the main source of physical change. Progressive overload works because the system being stressed is the same system that will adapt. Periodization works because an athlete can be modeled as a consistent unit across training blocks. Recovery metrics mean something because they're measured against a stable reference point.

When the system itself is changing rapidly and losing lean mass, adjusting nervous system tone, and operating under chronic caloric restriction, those standard frameworks need to be recalibrated. The body's state is shifting on a faster timeline than it typically would without the GLP-1, which means the gap between what we’re currently doing and what we probably should be doing to protect our long-term health can widen rapidly.

That gap is where the important questions are. Not "do GLP-1 medications affect performance?,” but "how do we track what our body is actually doing when the body itself is in the middle of a rapid transformation?"

References

1. Wilding, J.P.H., Batterham, R.L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. _https://doi.org/10.1056/NEJMoa2032183_

1. Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. _https://doi.org/10.1056/NEJMoa2206038_

1. Müller, T.D., Finan, B., Bloom, S.R., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. _https://doi.org/10.1016/j.molmet.2019.09.010_

1. Wadden, T.A., Bailey, T.S., Billings, L.K., et al. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA, 325(14), 1403–1413. _https://doi.org/10.1001/jama.2021.1831_

1. Biolo, G., Maggi, S.P., Williams, B.D., Tipton, K.D., & Wolfe, R.R. (1995). Increased rates of muscle protein turnover and amino acid transport after resistance exercise in humans. American Journal of Physiology – Endocrinology and Metabolism, 268(3), E514–E520. _https://doi.org/10.1152/ajpendo.1995.268.3.E514_

1. Heymsfield, S.B., Coleman, L.A., Miller, R., et al. (2021). Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity. JAMA Internal Medicine, 181(12), 1545–1554. _https://pmc.ncbi.nlm.nih.gov/articles/PMC7807292/_

1. Burguera, B., Tur, J., Escudero, A.J., et al. (2015). An intensive lifestyle intervention is an effective treatment of morbid obesity: the TRAMOMTANA study. Frontiers in Endocrinology, 6, 142. _https://doi.org/10.3389/fendo.2015.00142_